Status:
COMPLETED
Study Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The primary objective of this study is to compare the efficacy and safety of 3 dose levels of oral ERB-041 administered daily for 12 weeks versus placebo in subjects with active rheumatoid arthritis w...
Eligibility Criteria
Inclusion
- Clinical diagnosis of active rheumatoid arthritis for at least 6 months and on a stable dose of methotrexate for at least 12 weeks
- Rheumatoid arthritis onset after 16 years of age
Exclusion
- Any significant health problem other than rheumatoid arthritis
- History of male or female reproductive system cancer
- Clinically significant laboratory abnormalities
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 19 2006
Estimated Enrollment :
159 Patients enrolled
Trial Details
Trial ID
NCT00141830
Start Date
August 1 2005
End Date
October 19 2006
Last Update
September 29 2020
Active Locations (35)
Enter a location and click search to find clinical trials sorted by distance.
1
Largo, Florida, United States, 33773
2
Palm Harbor, Florida, United States, 34684
3
Sarasota, Florida, United States, 34239
4
Boise, Idaho, United States, 83702